Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP

Share this content:
For patients with chronic myeloid leukemia, prolonged imatinib use helps achieve deeper molecular response with long-term treatment.
For patients with chronic myeloid leukemia, prolonged imatinib use helps achieve deeper molecular response with long-term treatment.

For patients with chronic myeloid leukemia in chronic phase (CML-CP), prolonged imatinib use helps achieve deeper molecular response with long-term treatment, according to a study published in Clinical Lymphoma, Myeloma & Leukemia.1

Researchers retrospectively analyzed data from 131 patients with CML-CP who had undergone imatinib therapy; this was done to determine the frequency of complete molecular response and its clinical significance on patient outcomes and survival upon long-term follow-up.

Eighty-eight patients achieved complete molecular response upon median follow-up of 65 months. Rate of complete molecular response was higher for patients who achieved complete cytogenetic response at 12 months and major molecular response at 18 months.

RELATED: Combined Treatment May Lead to Cure for Chronic Myeloid Leukemia

Overall survival was not different between the 2 groups, and complete molecular response was associated with longer progression-free survival without statistical significance.

Reference

  1. Atagunduz IK, Toptas T, Deniz R, et al. Effects of deeper molecular responses on outcomes in chronic myeloid leukemia patients in chronic phase treated with imatinib mesylate. 2016 Sep 16. doi: 10.1016/j.clml.2016.09.006 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters